Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
September 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
Janssen’s Stelara becomes first European-approved biologic IL-12/IL-23 inhibitor for ulcerative colitis
September 5, 2019Sales and Marketing Europe, Janssen, Stelara, pharma, ulcerative colitis
Janssen has announced that its therapy Stelara (ustekinumab) hass secured a label expansion from the European Commission, approving the drug …
BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
September 5, 2019Research and Development BMS, glioblastoma multiforme, opdivo, pharma
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …
Cancer drugs have surged since the 80s to account for 1 in 4 FDA approvals, report reveals
September 5, 2019Research and Development, Sales and Marketing Cancer, FDA, US, pharma
The number of cancer drug approvals in the US has surged over the last decade to account for over one …
Ireland will not suffer immediate medicine shortages in event of no-deal Brexit, says health authority
September 5, 2019Medical Communications, Sales and Marketing England, Ireland, UK, brexit, pharma
Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the …
Key legal considerations in accelerating pharma using artificial intelligence
September 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, artificial intelligence, pharma
Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from …
FREE WEBINAR: Leveraging technology for optimal engagement
September 4, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Webinar, Within3, pharma
Join Pharmafocus and Within3 for a special webinar event on Thursday, 19 September, for a session exploring the changing trends …
Keytruda scores EU approval in combination with Inlyta for first-line advanced renal cell carcinoma
September 4, 2019Research and Development, Sales and Marketing EU, Europe, MSD, keytruda, pharma, renal cell carcinoma
The European Commission has awarded yet another authorisation in the region to MSD’s Keytruda, this time in combination with the …
Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis
September 4, 2019Research and Development Ardelyx, pharma, tenapanor
Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at …
NICE recommends Novartis’ gene therapy Luxturna for inherited retinal dystrophy
September 4, 2019Research and Development, Sales and Marketing Luxturna, NHS, NICE, UK, gene therapy, pharma
NICE has chosen to recommend the use of Novartis’ one-time gene therapy Luxturna (voretigene neparvovec) for use on the NHS …
AZ’s Tagrisso secures China approval in first-line advanced lung cancer
September 4, 2019Research and Development, Sales and Marketing AstraZeneca, China, Tagrisso, lung cancer, pharma
AstraZeneca’s Tagrisso (osimertinib) has secured approval in China from the country’s National Medical Products Administration (NMPA) in the first-line treatment …
Sandoz acquires global commercialisation rights to Polpharma’s multiple sclerosis biosimilar
September 3, 2019Manufacturing and Production, Sales and Marketing Polpharma, Sandoz, biosimilar, multiple sclerosis, pharma
Sandoz has revealed that it has sealed a deal with Polpharma Biologics to commercialise the latter’s proposed biosimilar version of …
NICE issues new quality standard for cerebal palsy treatment
September 3, 2019Manufacturing and Production, Research and Development
NICE has moved to publish a draft quality standard on the treatment of cerebral palsy (CP) in adults, it has …
Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis
September 3, 2019Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma
New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …
AstraZeneca shows off Farxiga heart failure efficacy at ESC 2019
September 3, 2019Manufacturing and Production, Research and Development
AstraZeneca has revealed new Phase 3 data illustrating that Farxiga (dapagliflozin), in combination with standard of care, met its primary …
University of Limerick’s Pharmaceutical Manufacturing Technology Centre to expand operations with €5m funding injection
September 3, 2019Manufacturing and Production Ireland, UK, pharma
The Pharmaceutical Manufacturing Technology Centre (PMTC) at the University of Limerick’s Bernal Institute in Ireland has secured €5 million ($5.5 …
Mylan gets provisional FDA greenlight for generic version of Lilly’s blockbuster cancer drug Alimta
September 2, 2019Sales and Marketing Alimta, Cancer, Eli Lilly, FDA, Mylan, pharma
Mylan has scored a preliminary approval in the US from the FDA for its generic version of Eli Lilly’s blockbuster …
No-deal Brexit will “make the disintegration of the health service an ever more real prospect”, BMA warns
September 2, 2019Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMA, NHS, UK, brexit, pharma
As the UK hurtles towards a catastrophic and autocratic exit from the European Union, the British Medical Association (BMA) has …
AstraZeneca presents strong Phase 3 Brilinta data for reducing CV risk
September 2, 2019Research and Development, Sales and Marketing AstraZeneca, Brilinta, pharma
AstraZeneca has unveiled new positive Phase 3 data on the efficacy of Brilinta (ticagrelor) in combination with aspirin, showing that …
Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients
September 2, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
